92% Accuracy In Early Parkinson's Classification

A common primary endpoint in pivotal clinical studies of Parkinson’s Disease (PD) is a rating scale completed in part by patients/caregivers and in part by clinicians. While this traditional assessment, the Unified Parkinson’s Disease Rating Scale (UPDRS), is qualified by regulators, it is an imperfect stand-alone tool for characterizing disease, as it is episodic and can be subjective. Drug developers and clinicians have long sought biomarkers than can generate more objective, richer, quantitative metrics of disease probability, severity, and risk for progression.

The Clinical ink team partnered with the University of Rochester and two bio-pharmaceutical companies on WATCH-PD to explore the viability of consumer grade digital health technologies (DHTs) as a method for capturing patient data to complement traditional in-clinic measures.